U.S. patent application number 11/731520 was filed with the patent office on 2007-08-02 for treatment of vision disorders using electrical, light, and/or sound energy.
Invention is credited to Thomas W. Harold.
Application Number | 20070179564 11/731520 |
Document ID | / |
Family ID | 34865404 |
Filed Date | 2007-08-02 |
United States Patent
Application |
20070179564 |
Kind Code |
A1 |
Harold; Thomas W. |
August 2, 2007 |
Treatment of vision disorders using electrical, light, and/or sound
energy
Abstract
A non-invasive ocular therapy for vision disorders is provided.
First and second electrodes of a direct current source are
electrically contacted so as to deliver current to and/or about an
area proximal one or more eyes of a subject. A direct electrical
current of between about 1-800 microamps, at a resistance
assumption of about 500 ohms, is generated between the electrodes
for a preselected duration. Preferably, the direct electrical
current is generated at a select frequency profile as a function of
time, and with a carrier signal of about 10,000-12,000 hertz.
Advantageously, the subject therapy is augmented via application of
light energy to the eye(s), as well as by the application of
infrasonic sound waves directly into eyes.
Inventors: |
Harold; Thomas W.;
(Chanhassen, MN) |
Correspondence
Address: |
NAWROCKI, ROONEY & SIVERTSON;SUITE 401, BROADWAY PLACE EAST
3433 BROADWAY STREET NORTHEAST
MINNEAPOLIS
MN
554133009
US
|
Family ID: |
34865404 |
Appl. No.: |
11/731520 |
Filed: |
March 30, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10565544 |
Jan 23, 2006 |
|
|
|
PCT/US05/03695 |
Feb 7, 2005 |
|
|
|
11731520 |
Mar 30, 2007 |
|
|
|
60542768 |
Feb 6, 2004 |
|
|
|
60542442 |
Feb 6, 2004 |
|
|
|
60542443 |
Feb 6, 2004 |
|
|
|
60542724 |
Feb 6, 2004 |
|
|
|
Current U.S.
Class: |
607/53 |
Current CPC
Class: |
A61N 1/36046 20130101;
A61N 1/326 20130101; A61N 2005/0651 20130101; A61N 2005/0663
20130101 |
Class at
Publication: |
607/053 |
International
Class: |
A61N 1/32 20060101
A61N001/32 |
Claims
1-29. (canceled)
30. A non-invasive ocular therapy for vision disorders comprising:
a. electrically contacting a first electrode of a direct current
source proximal an eye of a subject; b. electrically contacting a
second electrode of the direct current source to the subject; and,
c. causing an amplitude modulated pulsed carrier signal to pass
from one of said electrodes to another of said electrodes, said
amplitude modulated pulsed carrier signal being characterized by a
polarity inversion.
31. The therapy of claim 30 wherein said polarity inversion is
constant.
32. The therapy of claim 30 wherein said polarity inversion is
periodic.
33. The therapy of claim 30 wherein the pulsed carrier signal of
said amplitude modulated pulsed carrier signal is amplitudinally
modulated by a preselect frequency profile sequence.
34. The therapy of claim 33 wherein said preselected frequency
profile sequence comprises at least two unique frequencies.
35. The therapy of claim 33 wherein said preselected frequency
profile sequence comprises at least three unique frequencies.
36. The therapy of claim 33 wherein said preselected frequency
profile sequence comprises at least four unique frequencies.
37. The therapy of claim 33 wherein a frequency of said preselected
frequency profile sequence comprises a frequency in a range of
about 250-300 Hz.
38. The therapy of claim 33 wherein a frequency of said preselected
frequency profile sequence comprises a frequency in a range of
about 25-35 Hz.
39. The therapy of claim 33 wherein a frequency of said preselected
frequency profile sequence comprises a frequency in a range of
about 7-10 Hz.
40. The therapy of claim 33 wherein a frequency of said preselected
frequency profile sequence comprises a frequency in a range of
about 0.15-0.3 Hz.
41. The therapy of claim 40 wherein a frequency of said preselected
frequency profile sequence further comprises a frequency in a range
of about 25-35 Hz.
42. The therapy of claim 41 wherein a frequency of said preselected
frequency profile sequence further comprises a frequency in a range
of about 7-10 Hz.
43. The therapy of claim 42 wherein a frequency of said preselected
frequency profile sequence further comprises a frequency in a range
of about 0.15-0.3 Hz.
44. The therapy of claim 30 further comprising select application
of spectral components of visible light to an eye of the
subject.
45. The therapy of claim 44 wherein spectral components of visible
light of said select application of spectral components of visible
light are selected from the group consisting of blue, green, yellow
and red spectral components.
46. The therapy of claim 45 wherein said select application of
spectral components of visible light comprises a sequential
delivery of at least two spectral components of visible light.
47. The therapy of claim 44 further comprising select application
of infrasonic sound waves to the eye of the subject.
48. The therapy of claim 30 further comprising select application
of infrasonic sound waves to the eye of the subject.
49. The therapy of claim 48 wherein said infrasonic sound waves are
characterized by frequencies in a range from about 8-14 Hz.
50. An ocular therapy for vision disorders comprising directing an
inverted pulsed carrier signal through a vision disorder subject,
said inverted pulsed carrier signal being amplitudinally modulated
by a preselect frequency sequence.
51. The ocular therapy of claim 50 wherein said preselect frequency
sequence comprises up to four discrete amplitude modulating
frequencies.
52. The ocular therapy of claim 51 wherein said up to four discrete
amplitude modulating frequencies includes those selected from a
range of about either 250-300 Hz, 25-35 Hz, 7-10 Hz, and/or
0.15-0.3 Hz.
53. The ocular therapy of claim 50 wherein said preselect frequency
sequence comprises a first frequency in a range of about 250-300
Hz.
54. The ocular therapy of claim 53 wherein said preselect frequency
sequence comprises a second frequency in a range of about 25-35
Hz.
55. The ocular therapy of claim 54 wherein said preselect frequency
sequence comprises a third frequency in a range of about 7-10
Hz.
56. The ocular therapy of claim 55 wherein said preselect frequency
sequence comprises a fourth frequency in a range of about 0.15-0.3
Hz.
57. The ocular therapy of claim 50 further comprising select
application of either of blue, green, yellow or red components of
visible light to an eye of the vision disorder subject.
58. The ocular therapy of claim 57 further comprising select
application of infrasonic sound waves to the eye of the vision
disorder subject.
59. The ocular therapy of claim 50 further comprising select
application of infrasonic sound waves to an eye of the vision
disorder subject.
60. An apparatus for delivery of non-invasive ocular therapy for
vision disorders comprising a head supportable structure equipped
with an electrode and means for selectively delivering one or more
spectral components of visible light to an eye of a wearer of the
head supportable structure, said head supportable structure adapted
to pass an amplitude modulated pulsed carrier signal to/from said
electrode, said amplitude modulated pulsed carrier signal being
characterized by a polarity inversion.
61. The apparatus of claim 51 wherein said head supportable
structure further includes means for selectively emitting
infrasonic sound waves into the eye of a wearer of the head
supportable structure.
Description
[0001] This is an international patent application filed under 35
U.S.C. .sctn.363 claiming priority under 35 U.S.C. .sctn.119(e)(1)
of the following U.S. provisional patent applications: Appl. Ser.
No. 60/542,768 filed Feb. 6, 2004; Appl. Ser. No. 60/542,442 filed
Feb. 6, 2004; Appl. Ser. No. 60/542,443 filed Feb. 6, 2004; and,
Appl. Ser. No. 60/542,724 filed Feb. 6, 2004.
TECHNICAL FIELD
[0002] This invention relates to the treatment of vision disorders
(e.g., ocular disease), more particularly, the selective
therapeutic application of energy, in the form of electrical, light
and/or sound energy, to the eye(s).
BACKGROUND OF THE INVENTION
[0003] News and knowledge of vision disorders are on the rise. It
is estimated that the lifetime costs for all people with vision
impairment who were born in 2000 will total $2.5 billion (2003
dollars, see generally, Centers for Disease Control and Prevention,
Economic Costs Associated with Mental Retardation, Cerebral Palsy,
Hearing Loss, & Vision Impairment, United States, 2003, MMWR
2004; 53:57-9) . These costs include both direct and indirect
costs. Direct medical costs, such as doctor visits, prescription
drugs, and inpatient hospital stays, make up 6% of these costs.
Direct nonmedical expenses, such as home modifications and special
education, make up 16% of the costs. Indirect costs, which include
the value of lost wages when a person dies early, cannot work, or
is limited in the amount or type of work he or she can do, make up
77% of the costs. These estimates do not include other expenses,
such as hospital outpatient visits, emergency department visits,
and family out-of-pocket expenses. The actual economic costs of
vision impairment are, therefore, even higher than what is
generally reported.
[0004] The most common causes of vision impairment among adults in
the United States are age-related macular degeneration (AMD),
presbyopia, diabetic retinopathy, cataracts, and glaucoma. AMD
affects the part of the retina that is responsible for sharp
central vision and is the leading cause of legal blindness in the
United States in persons over 65 years old. According to a March
1997 Review of Optometry Journal, 10% of our population over age 52
has AMD and 33% of individuals over age 75 have AMD. It is
estimated that more than 13 million Americans now have AMD and
that, by the time the Baby Boomers reach age 65, there will be over
30 million cases of AMD, almost 25% of our population over 65.
[0005] Presbyopia is a frustrating condition that begins to effect
the "small print" visual acuity (i.e., blurred vision) of many
individuals after they reach forty years of age. People find that
they are unable to focus on the small print, and may develop
headaches, eyestrain, or feel fatigued. Treatment typically
involves buying inexpensive, "off-the-shelf" "reading glasses",
surgery, or bi-focal contact lenses. It is believed that presbyopia
occurs from a loss of elasticity or flexibility in the natural lens
of the eye of those over forty years of age. During the age-related
process, the proteins in the lens begin to make the lens harder,
less elastic, with muscle fibers around the lens also effected. As
the lens requires elasticity to focus up close, with a diminished
or diminishing functionality, visual acuity is impacted.
[0006] Diabetic retinopathy is a common complication of diabetes in
which the blood vessels in the retina break down, leak, or become
blocked, leading to vision impairment. Cataracts are a clouding of
the eye's lens, which is normally clear. Glaucoma is increased
fluid and pressure within the eye that leads to enlargement of the
eyeball. The risk of vision loss from many of these conditions can
often be reduced if the condition is found early and treated.
[0007] Normal retinal cell function is a photochemical reaction
converting light energy to an electrical impulse which travels to
the brain and vision occurs. With AMD and other visual system
diseases, diseased, inflamed retinal cells eventually lose cell
function. Adenosine triphosphate (ATP) levels drop, protein
synthesis drops, the electrical resistance goes up, and cell
electricity potential goes down. Basically, the cells seem to go
dormant for a time before they die. It is believed that, if
electrical stimulation is provided to the cells before they die,
blood vessel permeability is increased, a more normal cellular
electrical potential will be achieved, the ATP levels will
increase, protein synthesis will occur again, and normal cell
metabolism will be restored.
[0008] Additionally, electrical stimulation appears to have a
healing effect on the small blood vessels in the retina, promoting
a more efficient delivery of nutrients to the retinal cells and a
more efficient uptake of proteins that can accumulate on the
retina. Thus, it is believed that microcurrent stimulation (i.e.,
the delivery of typically about less than 1,500 microamps) will
help rejuvenate the cells in the retina to slow or stop
degeneration of the eye due to AMD and the like. With the proper
microcurrent stimulation wave form and therapy procedures,
progressive vision disorders may be slowed or stopped in a large
number of people suffering therefrom.
[0009] For example, Fedorov et al., U.S. Pat. No. 5,147,284,
proposed to treat diseases of the optic nerve and retina by the
application of a pulsed 3.5 magnetic flux, the magnetic field
induction being from 0.1 T to 0.25 T. However the technique is
invasive, requiring exposure of the posterior portion of the
eyeball and optic nerve and introduction of the inducer into the
orbit.
[0010] Liss et al., U.S. Pat. No. 4,614,193, proposed to treat
glaucoma with the application of transcutaneous electrical
stimulation, more particularly, the application of pulsed
electrical current at a level less than 4 milliamperes, the pulse
trains occurring at 12-20 kHz, amplitude modulated at 8-20 hz, and
having a 3:1 duty cycle. Applying this waveform through electrodes
positioned on the temple and on the ipsilateral hand, Liss et al.
achieved an approximately 28% reduction in intraocular pressure in
the treated eye. To the knowledge of the inventor, passage of
electrical current through the eye, hereinafter "transocular
electrical conduction," has been used in the art for the treatment
of blindness disease, but has yet to be maximized as a vision
disorder therapy, as for example, via the selection and/or
combination of wave forms, power, duration, and frequencies.
[0011] Greenberg et al., U.S. Pat. No. 5,944,747, is generally
directed to a method of focused phosphene generation through deeper
intermediate retinal cellular electrical stimulation, to the
exclusion of direct galleon cellular electrical stimulation, via
the application of a long duration stimulation signal. Preferably,
the long duration stimulation signal is a biphasic signal having a
negative and positive phase pulse. It is further believed to be
advantageous to make such biphasic pulses simulate cathodic
monophasic pulses by using unequal amplitude phases.
[0012] It is suggested from Wallace et al., U.S. Pat. No. 5,522,864
that a direct current with a constant magnitude of 200 microamps
has show positive effect in treating ocular disease including
macular degeneration. Further, Jarding et al., U.S. Pat. Nos.
6,035,236 & 6,275,735, suggests that microcurrent stimulation,
vis-a-vis the application of microcurrent approximate to an eye
wherein the microcurrent has an amplitude of about 50-180 microamps
and comprises a sweep wave microcurrent signal produced by a sweep
wave signal generator, can improve vision in individuals suffering
from additional "blindness" causing diseases, including retinitis
pigmentosis. In these instances, the theory for improvement has to
do with bringing energy to dormant photo-receptor cells. The
inventor believes that the Wallace et al. effort is not expansive
enough in both varying the power level and frequency
selection/application duration, and further, that the Jarding et
al. efforts are too broad in not specifying especially effective
therapeutic frequencies. In the Jarding et al. case, this may be
due to Jarding et al. attempting to treat a broad range of diseases
including cancer which likely require technical considerations that
are different from those implicated in overcoming vision
disorders.
[0013] Thus there remains a need for an energy based treatment of
vision disorders that maximizes therapeutic effect. Furthermore, it
is believed advantageous to provide an energy based treatment that
includes electrical, light and sound energy forms, alone or in
select combination, to effectuate a therapeutic result in persons
suffering from vision disorders. Further still, it is believed that
improvements in transocular electrical conduction are achieved
utilizing specific frequencies, wave forms, durations, and power
algorithms in furtherance of maximizing subject visual
efficacy.
SUMMARY OF THE INVENTION
[0014] It is a primary object of the present invention to provide
an improved apparatus and method for the treatment of vision
disorders.
[0015] It is another object of the present invention to provide a
safe, improved, noninvasive method for the restoration of vision by
treating the eye with transocular conduction of electrical
current.
[0016] It is yet another object of the present invention to provide
a safe, improved, noninvasive method for the restoration of vision
by treating the eye with transocular conduction of electrical
current supplemented by other energy forms, namely, light and/or
sound energy.
[0017] These and other objects of the present invention are
attained by a direct current generator that produces an amplitude
modulated, low level, pulsed, direct current applied between
electrodes, one placed on or proximal a closed eyelid and the other
on a remote body location, e.g., a top of the subject's
corresponding hand.
[0018] Blindness disease, as a species of vision disorder, is a
debilitating ocular disease having hemorrhagic and exudative
variants, both of which are susceptible to safe and efficient
treatment by the subject invention. Treatment typically results in
amelioration of the ophthalmoscopic manifestations of the disorder,
and substantial restoration of central visual acuity. For the
purpose of this disclosure, "blindness disease" means macular
degeneration, presbyopia, retinitis pigmentosis and Stargardt's and
may include one or more of: diabetic retinopathy, glaucoma,
CMV-retinitis, Best's disease, macular dystrophy, optic neuritis,
ischemic anterior optic neuritis, Usher's syndrome, Leber's
congenital amaurosis, cone-rod dystrophy, cone dystrophy,
choroideremia and gyrate atrophy, central retinal artery occlusion,
central retinal vein occlusion, branch retinal artery occlusion,
branch retinal vein occlusion, central serous chorioretinopathy,
cystoid macular edema, ocular histomplasmosis, ocular
toxoplasmosis, retinopathy of prematurity, amblyopia, stabismus,
and nystagmus.
[0019] As to the subject invention, more specific features and
advantages obtained in view of those features will become apparent
with reference to the drawing figures and DETAILED DESCRIPTION OF
THE INVENTION.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Referring now to the drawings wherein like numerals are used
to designate like parts of the invention throughout the
figures:
[0021] FIG. 1 illustrates a human subject receiving treatment for a
vision disorder utilizing the application of microcurrent;
[0022] FIGS. 2-5 depict frequency output for each of the preferred
sequences of the frequency profile associated with the electrical
stimulation of the subject invention;
[0023] FIG. 6 is a tabulation of Snellen Chart results for a twelve
week study of a plurality of patients undergoing the electrical
stimulation of the subject invention; and,
[0024] FIG. 7-10 illustrate: Snellen acuity, kinetic fields:
horizontal effect in degrees; kinetic fields: vertical effect in
degrees; and, Humphrey 30-2, total errors data for pre and post
treatment subjects undergoing the electrical stimulation of the
subject invention.
DETAILED DESCRIPTION OF THE INVENTION
[0025] The subject therapy is non-invasive, and involves minimally
delivering a precise amount of tightly controlled electrical
current through electrodes applied to the skin at specific areas at
and/or near the eyes. A multi-frequency pulse generator, e.g., a
ScyFIX 600 microcurrent stimulator, commercially available from
ScyFIX, LLC of Minnesota, U.S.A., is advantageous for generating
direct electrical current between electrodes in furtherance of
therapy administration.
[0026] With reference to FIG. 1, there is shown a human subject 20
having at least a single closed lid of an eye 21 in contact with an
electrode 22. Electrode 22 is connected to the positive output of a
constant current generator 25 having a suitable power source
connected thereto or incorporated therein. The negative output of
the generator 25 is connected to a second electrode 24, which is
preferably attached to the skin at the proximal hand. When the
generator 25 is activated, a current loop is established that
extends, in order, from the generator 25 through electrode 22 and
eye 21 so as to terminate at the second electrode 24. The current
loop is completed at the generator 25.
[0027] In accordance with one aspect of the invention, a vision
disorder, more particularly, a blindness disease in a subject is
treated by the steps of: placing a first electrode of a direct
current source in electrical contact proximal one or more eyes of a
subject, as for example, in contact with a closed eyelid thereof;
placing a second electrode of the source in electrical contact with
a site remote from the position of the first electrode; and,
causing a pulsed direct current from 1 to 800 microamps, at a
resistance assumption of about 500 ohms, to flow between the
electrodes and through the subject for a preselect duration, e.g.,
about twenty minutes. In a preferred embodiment, up to four
discrete frequencies are utilized in the course of the preselected
duration, more particularly, a frequency profile is administered
wherein, for example, the frequency profile comprises a sequence of
about 290 Hz (i.e., 250-300 Hz) for about one minute; about 31 Hz
(i.e., 25-35 Hz) for about two minutes; about 8.9 Hz (7-10 Hz) for
either about seven or ten minutes (i.e., at least about seven
minutes); and, about 0.28 Hz (i.e., 0.15-0.3 Hz) for either about
seven or ten minutes (i.e., at least about seven minutes).
Associated frequency output charts for each of the preferred
sequences of the profile are depicted in FIGS. 2-5. The employed
frequencies are utilized to amplitude modulate a pulsed carrier
signal having a pulse frequency of about 10,000-12,000 Hz.
Advantageously, the carrier signal is switched on and off in time
and inverted about every 0.5 seconds by reversing the polarity of
the signal at the electrodes.
[0028] With general and passing references to FIGS. 6-10, FIG. 6 is
a tabulation of Snellen Chart results for a twelve week study of a
plurality of patients undergoing the electrical stimulation of the
subject invention. The paired columns represent pre/post treatment
Snellen chart results for right (i.e., OD) and left (i.e., OS)
eyes. FIGS. 7-10 illustrate: Snellen acuity, kinetic fields:
horizontal effect in degrees; kinetic fields: vertical effect in
degrees; and, Humphrey 30-2, total errors data for pre and post
treatment subjects undergoing the electrical stimulation of the
subject invention.
[0029] In accordance with another aspect of the therapy of the
subject invention, the source is a portable, battery powered
constant direct current generator which is affixed/affixable to the
subject. The subject is thus enabled to ambulate while the direct
current is flowing there-through. In some circumstances, it may be
desired that the eyelid not be closed during treatment. In that
case, the electrode of the eye may be positioned around the eye. A
frame, such as an eyeglass frame or other easily supportable head
structure (not shown), may be fitted with an electrode to position
and maintain such an electrode about or near the eye.
[0030] In an alternate embodiment of non-invasive ocular therapy
for vision disorders and the like, light energy is applied to one
or both eyes of the subject. Preferably, but not necessarily, light
energy is applied at a power density of up to about 4.5 joules
percentimeter squared. Furthermore, it appears especially
advantageous that the light energy have an optical power of about 5
milliwatts percentimeter squared, with the light energy preferably
applied at a frequency of about 145 Hz for up to about fifteen
minutes.
[0031] It is generally known that certain biochemical conditions in
the brain facilitate effective cortical plasticity such that new
functions can occur. Neurotransmitters trigger this biochemistry
and allow for additional synoptic connections to initiate movement
and growth in new directions. Colored light therapy is believed to
act as a powerful tool to stimulate the biochemistry of the brain
through the visual system by way of the retinal-hypothalamus brain
connection.
[0032] With regard to apparatus for effectuating heretofore
described therapies, an electrode-carrying structure (e.g., a
frame, head band or other head gear) may be fitted with known light
emitting devices capable of delivering or administering one or more
select frequencies. For example, LEDs or IREDs may be employed to
provide light energy of a desired frequency dependent upon the
particular blindness disease. Blue-green colors are believed useful
for macular degeneration, and other blindness diseases, while
red-yellow colors are believed useful for retinitus pigmentosis,
and related or similar blindness diseases. Particular wavelength
ranges that are believed to be useful are: about 450-500 nm (i.e.,
more generally, "blue"); about 520-570 nm (i.e., more generally,
"green"); about 565-590 nm ((i.e., more generally, "yellow"); and,
625-740 nm (i.e., more generally, "red"). Light therapy at, or
including, these wavelength ranges may be advantageously employed
for blindness disease.
[0033] In a specific embodiment of the subject therapy, light
energy is conducted upon each eye of the subject sequentially
between light energy characterized by first and second wavelength
ranges. For example, for macular degeneration, the described
"frame" or the like may be fitted to direct blue light into one eye
and green light into the other while allowing the "colors" to be
switched from one treatment cycle to the next, or during an
individual treatment cycle. Such approach, utilizing wavelength
ranges associated with red/yellow are believed advantageous in
treatment of retinitis pigmantosis.
[0034] In addition to the intraocular application of electrical
and/or light energy, as described above, it may be additionally
beneficial to direct infrasonic sound waves (i.e., those having a
frequency generally below 20 Hz) directly into the eye or eyes of
the subject. Emitters for such sound waves may be carried by the
above described frames, or an adaption thereof. It is believed
advantageous, in furtherance of treating vision disorders, to
direct infrasonic sound waves into the eye, preferably, but not
necessarily, at random frequencies ranging from about 8-14 Hz.
[0035] While the principles under which the invention produces its
beneficial effects are not fully understood, and without
restriction to a particular theory of operation, transocular
electrical conduction as practiced in accordance with the invention
may restore cellular electrical balance by changing potentials
across cell membranes. This may alter the levels of certain ions
and molecules toward a desirable equilibrium. Other physiological
effects are believed to be produced: reduction of alkalinity
proximate the passage of electrical current and the production of
low levels of hydrochloric acid; attraction of oxygen to the
region; localized vasoconstriction; reduction of local hemorrhage;
sedation; increased tonicity of local tissues; antisepsis;
production of desirable fibroplasia; and reduced neuromuscular
irritability. Stimulation through the eyes also allows access to
more then thirty-three percent of the total blood volume of the
body in a twenty minute treatment session. The blood consists of
many cells which exist to capture electro-magnetic energy to
control and direct biomechanical reactions. This also includes
animating and mineralizing the blood by adjusting the pH. Also,
with blindness disease, diseased, inflamed retinal cells eventually
lose cell function. Adenosine triphosphate (ATP) levels drop,
protein synthesis drops, the electrical resistance goes up, and
cell membrane electrical potential goes down. Basically, the cells
seem to go dormant for a time before they die. So, it is believed
that, if electrical stimulation is provided to the cells before
they die, blood vessel permeability is increased, a more normal
cellular electrical potential will be achieved, the ATP levels will
increase, and protein synthesis will occur again.
[0036] It is to be understood the aforementioned therapeutic
aspects of electrical, light and sound energy may be administered
independently of each other (i.e., each individually), or in one or
more select combinations/permutations thereof. Furthermore, there
are other variations of the subject invention, some of which will
become obvious to those skilled in the art. It will be understood
that this disclosure, in many respects, is only illustrative, and
is not intended to be limiting. Accordingly, the scope of the
subject invention is as defined in the language of the appended
claims.
* * * * *